Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.
about
HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activityScaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentAntibody promiscuity: Understanding the paradigm shift in antigen recognitionRecent strategies targeting HIV glycans in vaccine designDesigning synthetic vaccines for HIVHIV-1 antibodies from infection and vaccination: insights for guiding vaccine designAntigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cellsAiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidatesMultiple Modes of Binding Enhance the Affinity of DC-SIGN for High Mannose N-Linked Glycans Found on Viral GlycoproteinsA peptide inhibitor of HIV-1 neutralizing antibody 2G12 is not a structural mimic of the natural carbohydrate epitope on gp120Antibodies Raised Against Chlamydial Lipopolysaccharide Antigens Reveal Convergence in Germline Gene Usage and Differential Epitope RecognitionA nonself sugar mimic of the HIV glycan shield shows enhanced antigenicityComplex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeAntibody WN1 222-5 mimics Toll-like receptor 4 binding in the recognition of LPSStructural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Structural Basis for Enhanced HIV-1 Neutralization by a Dimeric Immunoglobulin G Form of the Glycan-Recognizing Antibody 2G12Vaccine-elicited primate antibodies use a distinct approach to the HIV-1 primary receptor binding site informing vaccine redesignGlobal shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1The good and evil of complement activation in HIV-1 infectionHigh-throughput profiling of anti-glycan humoral responses to SIV vaccination and challengeHigh mannose-binding lectin with preference for the cluster of alpha1-2-mannose from the green alga Boodlea coacta is a potent entry inhibitor of HIV-1 and influenza viruses.Glycan microarrays for decoding the glycome.A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGNInducing cross-clade neutralizing antibodies against HIV-1 by immunofocusingBroadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titersAnalysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals.Antibodies against Manalpha1,2-Manalpha1,2-Man oligosaccharide structures recognize envelope glycoproteins from HIV-1 and SIV strainsThermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.Dimeric 2G12 as a potent protection against HIV-1.Effects of neighboring glycans on antibody-carbohydrate interaction.Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.Synthetic carbohydrate antigens for HIV vaccine design.New insight on 2-naphthylmethyl (NAP) ether as a protecting group in carbohydrate synthesis: a divergent approach towards a high-mannose type oligosaccharide library.Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-FcEnvelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies.A strategy for phage display selection of functional domain-exchanged immunoglobulin scaffolds with high affinity for glycan targets.Very few substitutions in a germ line antibody are required to initiate significant domain exchange.
P2860
Q21076115-7EE223E1-8DBA-4726-BD13-9839B24F8321Q24650458-4DC73680-7489-48AB-B376-AB6CD26E9856Q26801316-18506BBE-34D6-4DE5-9C0F-B4A408CA7193Q26823603-0CE7643C-6661-44BB-93D7-07E6A3A0FC18Q26862617-BC8B2495-3744-451E-85C6-1434AECE86C1Q27022055-116E6B7B-0E0E-4198-8B02-EF85DD35D001Q27320687-517950B9-85A6-4FC3-994B-AE10DB790BC8Q27489000-E7971A2B-3A7B-4E9F-8DBD-9A08A801A724Q27643229-BAE5D669-28E2-4231-B7DC-CE9ED3B9E6B3Q27649541-F887EF9A-AFBC-4B43-BDA3-C47BA3973C8AQ27658569-711DD5F7-5FEB-4AE1-B817-A7E7427C9CC4Q27664589-F866BB3B-7C65-4A6A-9F59-3947C1D69EA1Q27674878-1D1E32C5-C23C-41E4-BA22-599FFECD9CE5Q27675260-B854C0B5-C506-4EAB-BD35-8CDAE1E17D02Q27675263-BCFE760C-D0DE-49E8-8ADE-FBD61691B286Q27678312-B858D63D-4D9B-424C-B194-9817DC87329EQ27680810-A10A1E0B-F944-4C5B-9128-E1EE5A42E2D7Q27681806-7FA99A09-8C41-4C30-AC20-4D078CADE090Q28250040-7CABC993-1511-405F-A7DC-08ABD413864DQ28275986-A1FA952B-20D7-4686-9DBA-718BB2A945D8Q30354064-F5F66A4C-84A4-4E15-B776-2A8872D193D7Q30401412-CFB31578-CC77-4797-A973-D47396082A99Q31004845-761690A9-873B-4FA8-9684-A5D2BA71962DQ31132248-E20F6551-C831-4757-87F0-E689FAC16054Q33321821-4122E43B-B43E-4669-B812-466D853F58E2Q33392865-8E2BCB3F-2F5E-4F51-A3E5-1883A800DE7EQ33444658-B05BB305-8EBB-4128-8BBF-351FAC11FB29Q33526340-8231778C-8489-4A5E-98E3-AB19CB19657EQ33627537-195AA3ED-1754-42F4-A0C4-5CF2C922127DQ33725587-369649A8-5AA4-4E22-8E68-DBD526017A75Q33780961-2ADF0E11-3146-46D1-9063-9C84DB5E7A41Q33817230-9FF14163-E8F4-46F9-9683-51B9BDF5B63EQ33840789-F4E52755-B07A-44A6-BF95-8BC578BCED84Q33895810-AFD05092-1DE3-4D4C-AB59-77FE83FEE763Q33909079-7D52133C-5957-47E0-968F-5F9877FFF4F2Q33953440-CEA12D39-1D19-473E-977B-0270C35D5830Q33984231-F223FDA4-11CA-4542-BE9D-85507408A951Q34016211-6D933502-47D8-4AF7-9555-747E64C61FFDQ34123202-B3719409-662F-4FF3-86C1-0C7A116D1341Q34178341-39EF86EF-61D2-4F12-A3AD-A46075B2E01B
P2860
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@ast
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@en
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@nl
type
label
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@ast
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@en
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@nl
prefLabel
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@ast
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@en
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@nl
P2093
P2860
P921
P356
P1476
Dissection of the carbohydrate ...... zing anti-HIV-1 antibody 2G12.
@en
P2093
Cheng-Yuan Huang
Chi-Huey Wong
Daniel A Calarese
Dennis R Burton
Hermann Katinger
Hing-Ken Lee
Michael D Best
Rena D Astronomo
Robyn L Stanfield
P2860
P304
13372-13377
P356
10.1073/PNAS.0505763102
P407
P577
2005-09-07T00:00:00Z